Abstract
Neuroblastoma arises from precursor cells of the sympathetic nervous system and presently accounts for 15% of all childhood cancer deaths. These tumors display remarkable heterogeneity in clinical behavior, ranging from spontaneous regression to rapid progression and resistance to therapy. The clinical behavior of these tumors is associated with many factors, including patient age, histopathology and genetic abnormalities such as MYCN amplification. More recently, the dysregulation of some miRNAs, including the miR-17-5p-92 cluster and miR-34a, has been implicated in the pathobiology of neuroblastoma. MiR-17-5p-92 family members act in an oncogenic manner while miR-34a has tumor suppressor functions. The evidence for the contribution of miRNAs in the aggressive neuroblastoma phenotype is reviewed in this article, along with exciting possibilities for miRNA mediated therapeutics.
Keywords: MicroRNA, neuroblastoma, MYCN, chromosomal imbalance
Current Pharmaceutical Design
Title: MicroRNA Involvement in the Pathogenesis of Neuroblastoma: Potential for MicroRNA Mediated Therapeutics
Volume: 15 Issue: 4
Author(s): R. L. Stallings
Affiliation:
Keywords: MicroRNA, neuroblastoma, MYCN, chromosomal imbalance
Abstract: Neuroblastoma arises from precursor cells of the sympathetic nervous system and presently accounts for 15% of all childhood cancer deaths. These tumors display remarkable heterogeneity in clinical behavior, ranging from spontaneous regression to rapid progression and resistance to therapy. The clinical behavior of these tumors is associated with many factors, including patient age, histopathology and genetic abnormalities such as MYCN amplification. More recently, the dysregulation of some miRNAs, including the miR-17-5p-92 cluster and miR-34a, has been implicated in the pathobiology of neuroblastoma. MiR-17-5p-92 family members act in an oncogenic manner while miR-34a has tumor suppressor functions. The evidence for the contribution of miRNAs in the aggressive neuroblastoma phenotype is reviewed in this article, along with exciting possibilities for miRNA mediated therapeutics.
Export Options
About this article
Cite this article as:
Stallings L. R., MicroRNA Involvement in the Pathogenesis of Neuroblastoma: Potential for MicroRNA Mediated Therapeutics, Current Pharmaceutical Design 2009; 15 (4) . https://dx.doi.org/10.2174/138161209787315837
DOI https://dx.doi.org/10.2174/138161209787315837 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Magnetic Nanoparticles for MRI of Brain Tumors
Current Pharmaceutical Biotechnology Biosafety of Herpesvirus Vectors
Current Gene Therapy New Advances in Infant Feeding: New Products and Novel Technologies
Recent Patents on Food, Nutrition & Agriculture Leptin and the Regulation of Renal Sodium Handling and Renal Na+- Transporting ATPases: Role in the Pathogenesis of Arterial Hypertension
Current Cardiology Reviews Sirtuins and Resveratrol-Derived Compounds: A Model for Understanding the Beneficial Effects of the Mediterranean Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Mitochondria: “Mood Altering Organelles” that Impact Disease Throughout the Nervous System
Current Neurovascular Research Pharmacogenomics of COPD
Current Pharmacogenomics Gambogic Acid is a Novel Anti-cancer Agent that Inhibits Cell Proliferation, Angiogenesis and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Targets in Polycystic Liver Disease
Current Drug Targets Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Current Pharmaceutical Design Lactobacillus Rhamnosus Cell Lysate in the Management of Resistant Childhood Atopic Eczema
Inflammation & Allergy - Drug Targets (Discontinued) Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design FLT3 as a Therapeutic Target in Childhood Acute Leukemia
Current Drug Targets The Antiproliferative and Pro-apoptotic Effects of Methoxyamine on Pediatric Medulloblastoma Cell Lines Exposed to Ionizing Radiation and Chemotherapy
Central Nervous System Agents in Medicinal Chemistry Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Current Neuropharmacology Drug Repurposing for Retinoblastoma: Recent Advances
Current Topics in Medicinal Chemistry Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology Quality of Life of Children with Type 1 Diabetes: A Systematic Review
Current Diabetes Reviews Ontogeny of Hepatic Glucuronidation; Methods and Results
Current Drug Metabolism